Nolla Health Lets Utah Patients Get AI-Written Acne Prescriptions From a Face Scan

Nolla Health, a healthcare startup, said Monday that people in Utah can now use its app to photograph their faces and receive a prescription acne treatment, with the company's AI system assessing severity and writing the script on its own. The launch makes Utah the first state where the service is available, according to Bloomberg, which reported the news before the company's announcement. It is one of the first consumer-facing examples of an AI system issuing a prescription without a clinician signing off on the individual decision.

The mechanics are straightforward. A user opens the app, scans their face with a phone camera, and the software grades the acne and picks a treatment. From there, the system generates the prescription itself rather than handing an assessment to a doctor for approval. That autonomy is the part likely to draw scrutiny, since prescribing has traditionally been a licensed physician's act, even when the underlying diagnosis is routine.

Acne is a useful test case for automated prescribing because it is common, visually assessable and rarely dangerous. Dermatology has been one of the earliest medical specialties to absorb machine learning, largely because diagnosis leans on images rather than lab work or physical examination. Several companies already sell AI tools that flag skin conditions, but most keep a human in the loop before any drug is dispensed. Nolla is removing that step.

Utah has become a willing laboratory for this kind of arrangement. The state has passed laws encouraging so-called sandbox experiments in healthcare and fintech, which let companies test services under looser rules than a full national rollout would require. That makes it a logical first market for a startup that needs regulatory cover before expanding. Whether other states follow depends on how their medical boards treat software that prescribes on its own.

The obvious questions are liability and oversight. If the AI misjudges a rash as acne, or misses a more serious condition that mimics it, it is not yet clear who answers for the error — the company, the prescribing physician nominally attached to the practice, or no one. Nolla has not said how it handles adverse outcomes or what happens when a scan is ambiguous. Regulators have generally allowed telehealth prescribing when a clinician reviews the case, and it is that review step the company is now testing the limits of.

Watch for two things. First, whether Utah's medical board or state legislators put conditions on the service, which would signal how far the sandbox really extends. Second, whether Nolla expands to other states and conditions, since acne is a low-stakes entry point and the same architecture could point at far riskier prescriptions.